Graft vs Leukemia EffectBone Marrow TransplantationTransplantation, HomologousGraft vs Host DiseaseLeukemia, Myeloid, AcuteLeukemiaGraft vs Host ReactionBone MarrowLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL PositiveWhole-Body IrradiationBone Marrow CellsTransplantation ConditioningAnemia, AplasticTransplantation, AutologousGraft SurvivalAcute DiseaseBusulfanTransplantation ChimeraRemission InductionPrecursor Cell Lymphoblastic Leukemia-LymphomaGraft vs Tumor EffectTissue DonorsRecurrenceHematopoietic Stem Cell TransplantationHistocompatibility TestingLeukocyte TransfusionMyelodysplastic SyndromesCytarabineHistocompatibilityCyclophosphamideHematologic NeoplasmsTreatment OutcomeRadiation ChimeraLymphocyte DepletionHematopoietic Stem CellsTransplantation, IsogeneicLymphocyte TransfusionTime FactorsCombined Modality TherapyImmunosuppressive AgentsBone Marrow PurgingLeukemia, Myelomonocytic, AcuteBone and BonesHepatic Veno-Occlusive DiseaseSurvival AnalysisMice, Inbred C57BLT-LymphocytesHematopoiesisLeukemia, LymphoidChimeraImmunosuppressionAntineoplastic Combined Chemotherapy ProtocolsLeukemia, ExperimentalRetrospective StudiesCyclosporineLiver TransplantationLeukemia, Lymphocytic, Chronic, B-CellDaunorubicinNuclear FamilySurvival RateActuarial AnalysisTransplantation ImmunologyGene Expression Regulation, LeukemicDisease-Free SurvivalPrognosisfms-Like Tyrosine Kinase 3Graft RejectionFatal OutcomeHLA AntigensCytogeneticsNeoplasm, ResidualFusion Proteins, bcr-ablHematologic DiseasesMice, Inbred BALB CFollow-Up StudiesCytomegalovirus InfectionsLymphoma, Non-HodgkinAnemia, Refractory, with Excess of BlastsKaryotypingImmunophenotypingGranulocyte Colony-Stimulating FactorEtoposideFlow CytometryBone Marrow DiseasesLeukocyte CountLeukemia, Myeloid, Chronic-PhaseKidney TransplantationSevere Combined ImmunodeficiencyBone Marrow ExaminationStem Cell TransplantationPhiladelphia ChromosomeAntineoplastic AgentsLymphomaCell DifferentiationLeukemia, Monocytic, AcuteAntigens, CD34SpleenPancytopeniaMethotrexate